Dr. Reddy's Laboratories — patent litigation as defendant

I'll verify the company's profile with a few searches.

Company overview. Dr. Reddy's Laboratories Limited (commonly "Dr. Reddy's") is a publicly listed Indian multinational pharmaceutical company headquartered in Hyderabad, Telangana, India. It was founded in 1984 by Dr. Kallam Anji Reddy. It trades on the BSE (500124), NSE (DRREDDY) and as an ADR on the NYSE (RDY). It is not a subsidiary; it is an independent public company. Reported size is roughly 27,000+ employees worldwide, with FY2026 revenue around ₹290 billion / approximately US$3.5 billion (company investor materials; FT/PitchBook profiles give similar figures). It operates in over 100 countries.

Products / services / operations. Dr. Reddy's is an integrated pharmaceutical manufacturer, not a patent-assertion entity. Its segments are Global Generics (prescription and OTC finished dosages, plus biosimilars), Pharmaceutical Services and Active Ingredients (APIs, intermediates, contract research), and Proprietary Products/differentiated formulations. Major therapeutic areas include gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology; major markets are the US, India, Russia/CIS, Europe, China and Brazil. North America Generics is its largest market and a substantial ANDA filer (347 cumulative ANDA filings as of March 31, 2026, including many Paragraph IV filings).

Patent-litigation posture. Dr. Reddy's is an operating company defending against infringement suits, consistent with its single tracked appearance as a defendant and zero as a plaintiff. As a generic manufacturer, its litigation exposure typically arises from Hatch-Waxman Paragraph IV ANDA challenges filed by brand owners. The tracked case sits in the District of New Jersey, a common venue for ANDA litigation given the concentration of brand pharmaceutical companies there — not an NPE-favored venue like the Eastern District of Texas.

Notable cases / context. The one tracked matter is Helsinn Healthcare S.A. et al. v. Dr. Reddy's Laboratories, District of New Jersey, in which Dr. Reddy's is the defendant. The case data does not identify the specific patents or product at issue, and no merits should be inferred. Broader context: Dr. Reddy's is a serial ANDA litigant on the defense side and, like peers such as Teva and Sun Pharma, settles many such suits through licensing entry-date agreements.